IP Verse

Antibody Fc Variants - EP2691417

The patent EP2691417 was granted to Roche Glycart on Oct 30, 2024. The application was originally filed on Mar 27, 2012 under application number EP12710732A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2691417

ROCHE GLYCART
Application Number
EP12710732A
Filing Date
Mar 27, 2012
Status
Patent Maintained As Amended
Sep 27, 2024
Grant Date
Oct 30, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

MERCK PATENTMay 2, 2019ADMISSIBLE

Patent Citations (100) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0404097
DESCRIPTIONEP0425235
DESCRIPTIONEP1068241
DESCRIPTIONEP1692182
DESCRIPTIONUS2004214988
DESCRIPTIONUS2005079574
DESCRIPTIONUS2005119455
DESCRIPTIONUS2005260186
DESCRIPTIONUS2006025576
DESCRIPTIONUS2006104968
DESCRIPTIONUS2006134709
DESCRIPTIONUS2007061900
DESCRIPTIONUS2007117126
DESCRIPTIONUS2007160598
DESCRIPTIONUS2007237764
DESCRIPTIONUS2007292936
DESCRIPTIONUS2008069820
DESCRIPTIONUS2009002360
DESCRIPTIONUS2010166740
DESCRIPTIONUS4275149
DESCRIPTIONUS4318980
DESCRIPTIONUS4676980
DESCRIPTIONUS4737456
DESCRIPTIONUS4816567
DESCRIPTIONUS5091178
DESCRIPTIONUS5208020
DESCRIPTIONUS5416064
DESCRIPTIONUS5500362
DESCRIPTIONUS5571894
DESCRIPTIONUS5587458
DESCRIPTIONUS5624821
DESCRIPTIONUS5635483
DESCRIPTIONUS5648237
DESCRIPTIONUS5712374
DESCRIPTIONUS5714586
DESCRIPTIONUS5731168
DESCRIPTIONUS5739116
DESCRIPTIONUS5750373
DESCRIPTIONUS5767285
DESCRIPTIONUS5770429
DESCRIPTIONUS5770701
DESCRIPTIONUS5770710
DESCRIPTIONUS5773001
DESCRIPTIONUS5780588
DESCRIPTIONUS5789199
DESCRIPTIONUS5821337
DESCRIPTIONUS5840523
DESCRIPTIONUS5869046
DESCRIPTIONUS5877296
DESCRIPTIONUS5885573
DESCRIPTIONUS5959177
DESCRIPTIONUS6040498
DESCRIPTIONUS6075181
DESCRIPTIONUS6150584
DESCRIPTIONUS6171586
DESCRIPTIONUS6194551
DESCRIPTIONUS6248516
DESCRIPTIONUS6267958
DESCRIPTIONUS6417429
DESCRIPTIONUS6420548
DESCRIPTIONUS6586207
DESCRIPTIONUS6630579
DESCRIPTIONUS6737056
DESCRIPTIONUS6982321
DESCRIPTIONUS7041870
DESCRIPTIONUS7087409
DESCRIPTIONUS7125978
DESCRIPTIONUS7189826
DESCRIPTIONUS7498298
DESCRIPTIONUS7521541
DESCRIPTIONUS7527791
DESCRIPTIONWO03073238
DESCRIPTIONWO2004029207
DESCRIPTIONWO2005035727
DESCRIPTIONWO2005074524
DESCRIPTIONWO2005100402
DESCRIPTIONWO2006029879
DESCRIPTIONWO2006044908
DESCRIPTIONWO2006047350
DESCRIPTIONWO2006053301
DESCRIPTIONWO2006076594
DESCRIPTIONWO2009089004
DESCRIPTIONWO2009100309
DESCRIPTIONWO9301161
DESCRIPTIONWO9308829
DESCRIPTIONWO9316185
DESCRIPTIONWO9411026
DESCRIPTIONWO9848032
DESCRIPTIONWO9958572
EXAMINATIONUS2009068182
EXAMINATIONWO2005100402
INTERNATIONAL-SEARCH-REPORTUS2008274105
INTERNATIONAL-SEARCH-REPORTWO2009006520
OPPOSITIONEP2691417
OPPOSITIONEP2702074
OPPOSITIONUS2009215991
OPPOSITIONWO2006076594
OPPOSITIONWO2009023955
OPPOSITIONWO2012130831
OPPOSITIONWO2012146628

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- CARROLL R C ET AL, "Extensive C1q-complement initiated lysis of human platelets by IgG subclass murine monoclonal antibodies to the CD9 antigen", THROMBOSIS RESEARCH, TARRYTOWN, NY, US, vol. 59, no. 5, ISSN 0049-3848, (19900901), pages 831 - 839, (19900901), XP026360350-
OPPOSITION- JEFFERIS R; LUND J; POUND J D, "IGG-FC-MEDIATED EFFECTOR FUNCTIONS: MOLECULAR DEFINITION OF INTERACTION SITES FOR EFFECTOR LIGANDS AND THE ROLE OF GLYCOSYLATION", Immunological Reviews, (19980000), vol. 163, pages 59 - 76-
OPPOSITION- RUBINSTEIN et al., "Anti-Platelet Antibody Interactions with Fcgamma Receptor", Seminars in Thrombosis and Hemostasis, (19950000), vol. 21, no. 1, pages 10 - 22-
OPPOSITION- RUBINSTEIN et al., "Anti-Platelet Antibody Interactions with Fcgamma Receptor", Seminars in Thrombosis and Hemostasis, (19950000), vol. 21, no. 1, pages 10 - 22, XP055600691-
OPPOSITION- WINES et al., "The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc[gamma]RI and Fc[gamma]RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A", Journal of Immunology, (20000000), vol. 164, pages 5313 - 5318-
OPPOSITION- WINES et al., "The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc[gamma]RI and Fc[gamma]RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A", Journal of Immunology, (20000000), vol. 164, pages 5313 - 5318, XP002381581-
OPPOSITION- XU et al., "In vitro characterization of five humanized OKT3 effector function variant antibodies", Cellular Immunology, (20000000), vol. 200, pages 16 - 26-
OPPOSITION- XU et al., "In vitro characterization of five humanized OKT3 effector function variant antibodies", Cellular Immunology, (20000000), vol. 200, pages 16 - 26, XP002376698
OPPOSITION- JEFFERIS R; LUND J; POUND J D, "IGG-FC-MEDIATED EFFECTOR FUNCTIONS: MOLECULAR DEFINITION OF INTERACTION SITES FOR EFFECTOR LIGANDS AND THE ROLE OF GLYCOSYLATION", Immunological Reviews, (19980000), vol. 163, pages 59 - 76, XP001203450

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents